Genomics of Drug Sensitivity in Cancer

We have characterised 1000 human cancer cell lines and screened them with 100s of compounds.
On this website, you will find drug response data and genomic markers of sensitivity.

Our website and results are part of an ongoing research project. These webpages are updated frequently and our results are not final or complete.

What's new?

Release 8.5 (October 2023)

Release 8.5 fixes a bug in the fitting of dose response curves in the GDSC2 dataset for 39 compounds where the concentration range differs between cell lines. IC50 values are highly correlated between releases 8.4 and 8.5 for the 14106 curves affected - a minimum Pearson correlation per compound of 0.888. Removing SN-38 from the dataset improves the minimum correlation to 0.995. The GDSC1 dataset remains unchanged from release 8.4.


from 2010 to 2015 ✓ NEW
970 Cell lines 969 Cell lines
403 Compounds 297 Compounds
333292 IC50s 243466 IC50s
Resazurin or Syto60 CellTitreGlo
72 hours 72 hours

Key Publications

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.
Yang et al., (2013) Nucl. Acids Res. 41 (Database issue): D955 - D961. (PMID:23180760 )

A landscape of pharmacogenomic interactions in cancer
Iorio et al., (2016). Cell, Volume 166, Issue 3, 740 - 754 (PMID:27397505 )

Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett et al., (2012) Nature volume 483, pages 570 – 575 (PMID:27397505 )

Mailing List

To receive news and data release alert, please sign up Translation-announce

Contact us | Cookies policy | Terms & Conditions. This site is hosted by the Wellcome Sanger Institute.